Cabaletta Bio
Latest round
- Series B
Last raised
- Jan 2019
Total raised
- $88M
Investors
- 7
About Cabaletta Bio
Cabaletta Bio Inc., founded in 2017 and headquartered in Philadelphia, US, specializes in cell therapies targeting autoimmune diseases., Michael Milone, and Steven Nichtberger, who have a history of entrepreneurship in the biotech sector.Cabaletta Bio, Inc. primarily focuses on developing innovative cell therapies for patients suffering from autoimmune diseases. Their core product, CABA-201, is an investigational CD19 Chimeric Antigen Receptor (CAR) T cell therapy designed to target diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. This therapy aims to achieve deep and durable responses by transiently eliminating B cells to potentially reset the immune system and promote remission. Currently, Cabaletta is conducting its RESET™ clinical trials, which are pivotal in assessing the safety and efficacy of CABA-201.Cabaletta Bio generates revenue through its clinical development programs and partnerships within the biotechnology sector, particularly focused on the commercialization of CABA-201. Revenue transactions typically arise from collaborations and agreements with healthcare institutions and research organizations involved in clinical trials. These relationships often encompass shared research agreements or potential licensing arrangements that can leverage Cabaletta's proprietary technologies.00 mn to complete preclinical development and submit the Investigational New Drug (IND) application for CABA-201, while also initiating its clinical development in multiple indications. Additionally, the company aims to advance ongoing clinical studies for its DSG3-CAART and MuSK-CAART product candidates. The strategic focus includes targeting expansion into new geographic markets in North America and Europe by 2024, where there is a significant demand for innovative therapies addressing autoimmune diseases.
Who invested in Cabaletta Bio
7 investors across 2 rounds
See all investors in Cabaletta Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cabaletta Bio
Who invested in Cabaletta Bio?
Cabaletta Bio has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cabaletta Bio raised?
Cabaletta Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Cabaletta Bio last raise money?
Cabaletta Bio's most recent round on record is a Series B, in Jan 2019.
What does Cabaletta Bio do?
Cabaletta Bio is a biotechnology company.
Where is Cabaletta Bio headquartered?
Cabaletta Bio is headquartered in Philadelphia, US.
Which VCs invest in companies like Cabaletta Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Cabaletta Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Cabaletta Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.